The biotechnology company reports promising new pharmacology data for its FAP-Exd cancer drug candidate, highlighting its tumor-specific activity and potential to address high unmet needs.
The biotechnology company reports positive Phase 1b data for its lead drug candidate in treating a rare form of head and neck cancer, demonstrating tumor shrinkage in patients.
The life sciences company announces preliminary data from a Phase 1b trial for its cancer therapy candidate.
The healthcare company has completed a placing and transaction to increase its share capital.
The biotechnology company has presented preclinical data on its innovative dual payload cancer therapy, which aims to overcome resistance and maximize tumor control.
The biopharmaceutical company will present data on its pre|CISION® oncology delivery platform at an investor event.
The biotechnology company has raised £16 million through a discounted equity placing to fund the advancement of its oncology pipeline.
The biopharmaceutical company has presented positive Phase 1a data for its lead program, faridoxorubicin, demonstrating favorable safety and tolerability as well as promising efficacy in certain cancer types.
The biopharmaceutical company announces it will present data on its first dual-payload PDC at an upcoming cancer therapeutics conference, showcasing its innovative oncology delivery platform.
The clinical-stage biotech firm reports progress in its cancer therapy trials, but faces financial headwinds with flat revenue and decreasing net assets.